FINE-ONE
Summary
In this study, participants with type 1 diabetes will take a new medication that has been shown to reduce kidney disease in people living with type 2 diabetes. This medication is called finerenone. No other medication on the market has been shown to reduce kidney disease. Participants will visit with a study nurse about 6 times over 7 months to get study medication and complete blood work.
Eligibility
Eligible ages: 18 to 100
Inclusion criteria:
1. Over 18 years of age
2. Living with Type 1 Diabetes
3. Have been diagnosed with chronic kidney disease (CKD)
Exclusion criteria:
1. People with Type 2 Diabetes
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
Amy Dunlop
Principal investigator:
Ronald Sigal
Clinical trial:
Yes
REB-ID:
REB23-0867